• Established and led the cross-site (US and UK) Clinical Immuno-Oncology (IO) team within Early Oncology Discovery to provide strategic and tactical leadership to support and enable the development of the IO biologics portfolio assets following IND filingo Current IO biologics portfolio of 10 assets and 1 priority workstreamo Team formed to maximize the success of Early- and Late-stage clinical trials, drug registration and after market approval • Developed and executed team strategy through partnership with critical AZ functions• Shaped the internal scientific investment, anticipated investment needs, and ensured provisions for appropriate resourcing aligned to the strategic vision of each clinical stage project• Worked closely with Late Oncology disease area teams (Breast, Lung, Hematology, GU, GI and Pediatric) acting as the interface between Early and Late Oncology.• Developed and maintained effective relationships across Early and Late Oncology functions to ensure resources were aligned for internal portfolio delivery plan and risks were managed -- enabled effective operation in a highly matrixed environment• Recommended, secured funding for, and developed external partnerships with leaders in the field• Accelerated pipeline delivery through focusing on ways to enable the unit to act nimbly and innovatively to ensure rapid development and decisions in a highly competitive landscape• Developed a high performing, integrated, multi-site team - instilled a culture of agility and innovation - fostered a working environment that promoted science and encouraged innovation on drug discovery and global ways of working• Recruited the necessary expertise as needed while also providing opportunities for expanded learning, career development and advancement within the team• Ensured external influences in the rapidly changing external landscape – competition, regulatory changes, etc. – were well understood and incorporated into the overall strategy

• Developed and implemented strategy for the immunotherapy portfolio in Early Discovery Oncology• Discovered and developed immunotherapy biologic drugs as project and/or pharmacology leader from target identification through PoC (Phase 2 clinical trials) including regulatory filings and communications with regulatory authorities; 9 NME IND filings including durvalumab and blinatumomab• Oversaw and coached a team of PhD scientists leading internally developed projects, externally licensed programs, or various levels of pharmacology support of programs• Developed, managed and leveraged external collaborations and alliances with investigators in industry and academia in support of discovery and clinical stage programs• Worked closely with senior leadership and peers of each line function (Research, Clinical Development and Operations, Translational Sciences, Legal, Regulatory, Development, Commercial, Project Management, iMED, etc) at multiple sites (Cambridge UK, Hayward CA, Watham MA, Alderley Park UK, Japan, China) to manage and create seamless and integrated development processes for project progression and decisions• Developed novel cell-based assays and in vivo mouse models to identify lead candidate biologic therapies (ie, antibodies and fusion proteins) in support of project progression• Managed the implementation of pharmacodynamic endpoints to assess target and immune population effects as well as standard markers of tumor proliferation and apoptosis• Hired, managed and developed a unified team of up to 26 PhD and non-PhD scientists; thesis advisor for MS and PhD students• Evaluated in-licensing opportunities for novel cancer targets, therapeutic drugs, and technologies • Peer-reviewed manuscripts, patent applications and speaker invitations demonstrates expertise and accomplishments

• Managed and performed immunology-based discovery research using transcutaneous immunization methods in pre-clinical animal models targeting infectious disease agents• Initiated and assisted in the development of cancer immunotherapy program - Managed and completed proof-of-concept prophylactic tumor vaccine program using a model tumor associated antigen - Identified and brought in-house the candidate human tumor antigen Cyclin B1 from the University of Pittsburgh for pre-clinical evaluation and product development• Authored section of funded 5 year NIH P01 Program Project grant on development of HIV-1 antigen vaccine patch and directed Iomai’s grant-related activities • Developed, conducted, and optimized novel immunological and cell biology assays• Coordinated and performed vaccine research and development activities with commercial and academic partners